InnovAge Q1 FY27: Net Income Triples to $20.9M; DOJ Settlement Paid, Derivative Deal Collapses
INNV has more than doubled off its 52-week low of $3.935.
Summary
InnovAge opened fiscal 2027 with revenue up 12.1% to $264.8M and net income of $20.9M versus $7.7M, while paying a ~$36.9M DOJ/state False Claims Act settlement and losing court approval of its derivative settlement.
Key Events · Earnings and Guidance · INNV
-
Q1 Revenue Up 12.1%, Profit Triples
Total revenue of $264.8M versus $236.1M a year ago; net income $20.9M versus $7.7M, with diluted EPS of $0.14 versus $0.06.
-
Adjusted EBITDA Jumps to $31.3M
Adjusted EBITDA margin expanded to 11.8% from 7.5%, and center-level contribution margin rose to $63.6M (24.0% of revenue) from $51.4M (21.8%).
-
DOJ False Claims Settlement Paid
October 2026 agreements with the DOJ and California, Colorado, New Mexico and Virginia required aggregate payments of approximately $36.9M, made at the end of October against a $36.7M accrual.
-
Derivative Settlement Approval Denied
The Delaware Court of Chancery denied approval of the stockholder derivative settlement on October 7, 2026; the company served notice of intent to terminate on October 21, 2026, and cannot estimate a loss range.
Analysis · INNV · Industrial Applications And Services
InnovAge's fiscal Q1 profit more than doubled as revenue grew 12.1% to $264.8M and operating income reached $20.2M, with Adjusted EBITDA of $31.3M (11.8% margin) versus $17.6M a year ago. The quarter also closed out the long-running False Claims Act matter: settlement agreements with the DOJ and California, Colorado, New Mexico and Virginia required roughly $36.9M paid at the end of October, against a $36.7M accrual, removing a multi-year overhang. Cash rose to $119.3M from $97.9M. The offsetting negative is legal and regulatory: the Delaware Chancery denied approval of the stockholder derivative settlement on October 7 and the company moved to terminate it on October 21, leaving that case unresolved with no estimable loss range, while new PACE moratoriums in Colorado (through at least October 2028) and California (through at least November 2027) constrain de novo expansion. Management also flagged expected Medicaid rate pressure in Colorado retroactive to July 1, 2026 and in California from January 1, 2027, which it says will hit fiscal 2027 margins.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INNV was trading at $8.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.94 to $12.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.